ID   HepG2-CYP3A29
AC   CVCL_A9JD
DR   cancercelllines; CVCL_A9JD
DR   Wikidata; Q108820459
RX   CelloPub=CLPUB00644;
CC   Population: Caucasian.
CC   Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line).
CC   Transfected with: VGNC; 103556; Pig CYP3A29.
CC   Transfected with: UniProtKB; P00552; Transposon Tn5 neo.
CC   Derived from site: In situ; Liver; UBERON=UBERON_0002107.
DI   NCIt; C3728; Hepatoblastoma
DI   ORDO; Orphanet_449; Hepatoblastoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0027 ! Hep-G2
SX   Male
AG   15Y
CA   Cancer cell line
DT   Created: 23-09-21; Last updated: 05-10-23; Version: 5
//
RX   CelloPub=CLPUB00644;
RA   Xue Z.-K., Wei H., Shang H.-T., Ye B.;
RT   "Establishment of a HepG2 cell line stably expressing the CYP3A29
RT   isoenzyme and identification of its nifedipine metabolic activity.";
RL   Zhongguo Ren Shou Gong Huan Bing Xue Bao 25:640-644(2009).
//